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In terms of the pathogenesis of cardiovascular disease (CVD) the focus has traditionally been on
dyslipidemia. Over the decades our understanding of the pathogenesis of CVD has increased, and infections,
including those caused by oral bacteria, are more likely involved in CVD progression than previously
thought. While many studies have now shown an association between periodontal disease and CVD, the
mechanisms underpinning this relationship remain unclear. This review gives a brief overview of the host-
bacterial interactions in periodontal disease and virulence factors of oral bacteria before discussing the
proposed mechanisms by which oral bacterial may facilitate the progression of CVD.
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C
ardiovascular disease (CVD) refers to diseases of
the circulatory system, including outcomes such
as myocardial infarction and stroke (1). CVD,
along with cancer, is a leading cause of death in Western
societies. According to Queensland Health, CVD was the
second highest cause of disease burden in Queensland in
2003, accounting for 17.8% of the overall burden of
disease (number of lives lost due to premature mortality
and disability: DALY) with 77% of the cardiovascular
(CV) burden attributed to premature mortality. With
regard to specific conditions, coronary heart disease
(CHD) was the major contributor to the burden of
disease, accounting for 10.2 and 10% of the DALYs
in Queensland and Australia, respectively (2). The
underlying cause of CVD in the majority of cases is
atherosclerosis (3). While great advances have been made
in the treatment of CVD, the prevalence of the disease
continues to rise. Up to 50% of individuals with CVD do
not have any of the traditional CV-risk factors such
as hypercholesterolemia, hypertension, smoking, and
obesity (4), indicating that other factors must contribute
to the disease. Identification of other risk factors for
CVD, along with their mechanisms of action, is essential
if morbidity and mortality from the disease are to be
reduced.
The roles of infection and inflammation in athero-
sclerosis have become increasingly apparent. Chronic
inflammatory periodontal diseases are among the most
common human infectionswith 1015% of the population
experiencing advanced forms of the disease (5, 6). In the
context of CVD, individuals with periodontitis are
reportedtohaveanincreasedriskofdevelopingthedisease,
including coronary artery disease, stroke, myocardial
infarction, and atherosclerosis even after adjusting for
classical CV-risk factors (711). Furthermore, adjusted
analysis showed that the bacterial burden of Porphyromo-
nas gingivalis, Actinobacillus actinomycetemcomitans,
Treponema denticola, and Tannerella forsythia in subgingi-
val plaque samples was associated with carotid intima-
media thickening (12).
While many studies have shown an association between
periodontal disease and CVD, some studies have shown a
weak or no association between the two diseases (1315).
The fact that periodontitis and CVD share common risk
factors also makes interpretation of the clinical studies
complex. Meta-analyses have been conducted, however,
and a small but significant association has been demon-
strated (1618). The atherosclerotic susceptible apolipo-
protein E deficient (apoE /) mouse model has
provided further support for the role of oral bacteria in
atherosclerosis by demonstrating that inoculation with P.
gingivalis results in advanced atherosclerotic lesions
compared with control mice (1921).
The present review will discuss the current proposed
mechanisms linking oral bacteria with CVD, focusing
specifically on direct endothelial invasion, systemic
inflammation, platelet aggregation, and cross-reactivity
between bacterial and host heat shock proteins.
(page number not for citation purpose)
 SYSTEMIC DISEASE AND ORAL BACTERIA
Journal of Oral Microbiology 2010. # 2010 Shaneen J. Leishman et al. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
1
Citation: Journal of Oral Microbiology 2010, 2: 5781 - DOI: 10.3402/jom.v2i0.5781Hostbacterial interactions in periodontal
disease
P.gingivalis,T.denticola,andT.forsythiaarepartofasmall
group of Gram-negative anaerobic bacteriathat havebeen
found to be involved as pathogens in many periodontitis
lesions and have been nominated as the red complex (22).
These organisms reside in a complex biofilm that is the
dental plaque. While these bacteria are associated with
periodontal disease progression, their complex relation-
ships with each other and the many commensal bacteria
present in the biofilm must be consideredwhen examining
the immune response occurring in periodontal disease.
There is considerable variation in the composition of this
biofilmthatisdeterminedbyfactorssuchastheindividual,
the site examined, and the time of the examination. The
biofilm is formed by colonization of the enamel salivary
pellicle followed by secondary colonization that occurs by
interbacterial adhesion (23). Subgingivalplaque, due toits
moreprotectedlocation,ismuchmoreresistanttoremoval
than supragingival plaque. Successful colonization of the
biofilm by a microorganism can be enhanced by adhesins
including fimbriae, hemagglutinins, and proteases (24).
P. gingivalis binds via fimbrillin (fimA), the structural
subunit of the major fimbriae. It is an asaccharolytic
organism and produces hemagglutinins and proteases for
its hemin and peptide requirements. The hemagglutinins
are also involved in bacterial adherence and the proteases
leadtoimmuneresponsesandtissue destruction (reviewed
in Gemmell and Seymour (25)). P. gingivalis is associated
with deep periodontal pockets and sites of active disease
(26). The pathogenicity of this organism is due to several
features including fimbriae, which enable its adherence to
and invasion of gingival tissues (27), a dense amorphous
capsule that allows resistance of phagocytosis, and pro-
duction of enzymes such as collagenase and trypsin-like
proteasethat facilitatestissuebreakdownanddegradation
of most serum proteins, including immunoglobulins
and complement components. P. gingivalis also inhibits
neutrophil migration into the lesion by its failure to
stimulate the expression of the neutrophil binding
adhesion molecule E-selectin on gingival endothelial cells
and by inhibition of epithelial cell production of inter-
leukin-8 (IL-8). Specific antibodies produced may be
ineffective, further inhibiting clearance by neutrophils
(reviewed in Gemmell et al. (28)).
A mouse model has been used to define the immune
response to P. gingivalis (29, 30) and variations in the
local T- and B-cell responses occurred with different
mouse strains. Interestingly, a study examining coinfec-
tion with P. gingivalis and Fusobacterium nucleatum
demonstrated inhibitory effects on antibody production
by both bacteria (31). F. nucleatum and P. gingivalis have
been shown to exert differential effects at the molecular
level on oral epithelial cells and their differences in
activating NK-kB nuclear translocation in oral epithelial
cells may at least in part be responsible for the change in
dynamics and kinetics of downstream gene expression
(32).
Cells of the periodontium, particularly epithelial
cells and inflammatory cells interact directly with
plaque bacteria and bacterial products. It is the result of
these interactions that ultimately determines whether the
inflammatory lesion will resolve, become stable, or lead
to progressive host tissue destruction. Studies using a
coculturemodel,therefore,haveyieldedusefulinformation
regarding these interactions. A macrophage/epithelial cell
coculture model assessing the effect of exposure to mono
and mixed preparations of whole cells of red-complex
bacteria examined cytokine production at varying multi-
plicitiesofinfection(MOI).SecretionofIL-1b,IL-6,IL-8,
and RANTES was increased and this varied with the
bacterial strain and MOI (33).
The ability of red-complex bacteria to suppress innate
immune responses of gingival epithelial cells has been
demonstrated in vitro. Orange-complex bacteria induced
strong responses while non-periodontopathic bacteria
elicited only weak responses from these cells (production
of human beta defensins, the cathelicidin LL-37, and the
neutrophil chemoattractant IL-8) (34). Interestingly, while
non-periodontopathic and orange-complex bacteria were
highly susceptible to the antimicrobial peptides produced
and to phagocytosis by neutrophils, red-complex bacteria
were resistant. Therefore, non-periodontopathic bacteria
may protect the host by activating the gingival epithelium
at low levels, orange-complex bacteria may be weakly
pathogenic (but have other roles in contributing to a
pathogenic biofilm) while red-complex bacteria can effec-
tively evade host immune mechanisms and establish
persistent infection.
In contrast to the results of in vitro models (33) in which
no synergistic effects were observed for mixed bacterial
stimulations, there is evidence that periodontopathic
bacteria act cooperatively in terms of the development
of a pathogenic biofilm and also in causing disease in
animal models (35, 36). A number of studies have
described the pathogenic synergism between P. gingivalis
together with F. nucleatum (37, 38), T. denticola (39), or
T. forsythia (40). It has been suggested that bacterial cell
cell interactions may enhance both the survival of the
organisms in a hostile environment and also their
pathogenicity (38).
Virulence factors of oral bacteria
Lipopolysaccharide (LPS)
Lipopolysaccharide (LPS) is a component of the
outer membrane of Gram-negative bacteria. The LPS is
recognized by the innate immune system by means of toll-
like receptors (TLRs). TLRs allow recognition of structu-
rally conserved pathogen associated microbial products
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(41)). Bacterial LPS is usually recognized by TLR-4; an
exception to this is LPS from P. gingivalis that, due to a
structuralchange,isrecognizedbyTLR-2(42).Ligationof
TLRs triggers signal transduction pathways leading to a
rapid innate inflammatory response and facilitation of
antigen specific acquired immunity (reviewed in Takeda
and Akira (41)).
CD14 acts as coreceptor with TLR-4 for the detection
of bacterial LPS. Increased levels of soluble CD14 in
serum of periodontal patients (43) along with increased
serum levels of antibodies against LPS of periodonto-
pathogens has been demonstrated (44), suggesting that
chronic exposure to bacterial LPS in these patients results
in systemic effects. Activation of CD14 leads to the
secretion of many proinflammatory molecules including
IL-1, IL-6, tumor necrosis factor-alpha (TNF-a), and
prostaglandin E2 (45) that, in turn, promotes the release
of secondary inflammatory mediators such as platelet
activation factor, bradykinin, histamine, and prostaglan-
dins (43, 44, 46, 47).
Bacterial LPS is also known to activate the comple-
ment system, a group of more than 30 proteins that
participate in tissue destruction and the inflammatory
process (45). Activation of the complement system is one
of the earliest host immune responses in periodontal
infection (reviewed in Genco (48)), and the degree of
complement system activation is related to the severity of
periodontal inflammation (49). Some oral bacteria are
able to avoid opsonization as they exhibit proteolytic
activity on their cell surface for degrading components of
the complement system (50).
Proteases
Proteases cleave peptide bonds and are characterized
according to their catalytic activity. P. gingivalis is able
to secrete large amounts of proteolytic enzymes. Among
the extracellular endopeptidases of P. gingivalis, cysteine
proteases, termed gingipains (Lys-gingipain, Kgp; Arg-
gingipain, Rgp), are major virulence factors. Their
activities are essential for bacterial survival but are
pathogenic to the host (reviewed in Imamura (51)).
Gingipains allow P. gingivalis to attach to host tissues by
facilitating fimbriae maturation and are also involved in
hemoglobin binding for collection of heme and host
amino acids, important nutrient sources for the bacteria
(reviewedinPotempaetal.(52))Theseenzymesareableto
degrade a broad range of proteins including collagens
(a major component of periodontal connective tissue)
(53) and extracellular matrix proteins (fibronectin and
laminin) (54, 55), leading to destruction of periodontal
tissue (56). Rgp and Kgp also cleave and inactivate
immunoglobulins (53) and cytokines (57, 58) thereby
compromising host defense mechanisms (52, 59).
As reported by Imamura (51), gingipains also cause
decreased IL-6 levels in gingival tissues near the bacterial
biofilm, suppressing inflammatory reactions mediated by
IL-6 and, therefore, facilitating periodontal tissue de-
struction. This finding is also confirmed by Oleksy et al.
(60), who identified the proteolysis of IL-6 receptors in
vitro by gingipains from P. gingivalis. In addition, other
cytokines including IL-8 and IL-1b were found to be
cleaved by gingipains (51). Dysregulation of the coagula-
tion cascade (61) and activation of the kallikrein-kinin
cascade have also been shown to be caused by Rgp and
Kgp (62). Furthermore, Rgp causes increased vascular
permeability (51) and produces a chemotactic factor to
attract leukocytes to migrate into the periodontal tissues
(63). Kgp activates the kallikrein-kinin system in the
intrinsic pathway of coagulation leading to the release of
bradykinin and prostaglandin thereby promoting alveo-
lar bone resorption (64, 65). Gingipains can also degrade
the CD14 receptor for bacterial LPS on the surface of
monocytes and T-cells leading to decreased responsive-
ness to LPS (51, 66, 67). Gingipains have also been shown
to stimulate and activate matrix metalloproteinases
(MMPs) that destroy periodontal tissue (51). These
effects, which lead to enhanced tissue damage, may also
help bacteria to enter the blood stream.
AmurineabscessmodelusingaP.gingivalisstrainwitha
gingipain mutation showed reduced abscess size (40),
reduced proteolytic, hemagglutinating, and colonizing
activity (6870), as well as weakened polymorphonuclear
leukocyte-suppressive activities (56). Additionally,
bacterial clearance was greater in mice injected with P.
gingivalis gingipain mutants (71). This may be due to the
fact that gingipains are important in the maturation of
fimA, an important component supporting bacterial
adhesion and invasion (59, 72). Additionally, lack of
gingipains will prevent bacteria from obtaining heme, a
nutrition source required for their growth and develop-
ment (72, 73). Supporting this finding, P. gingivalis grown
in heme-limiting cultures has been reported to become
avirulent in a mouse model (74). Immunization with
gingipain in a mouse model protected against further
infection by P. gingivalis (75, 76).
Fimbriae
Fimbriae are hair-like protein structures protruding from
the cell surface of bacteria, particularly Gram-negative
bacteria. Fimbriae assist in the binding of bacteria to
host cells, as well as in colonization and resisting host
defenses (77). fimA of P. gingivalis has been the most
extensively studied and is a critical factor in supporting
the initial adhesion and invasion of bacteria to target cells
as well as for its colonization on gingival tissues (78, 79).
A strain of P. gingivalis with mutations in the fimA genes
showed loss or reduction in adherence or invasion of
host cells (80, 81). In vitro, P. gingivalis has been shown
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periodontal ligament cells (78, 82, 83).
Six genotypes of fimAf r o mP. gingivalis (types IVand
Ib) have been classified according to their different
nucleotide sequence (8486). Type II fimA and type IV
fimA are believed to be more virulent and have been
found to be more prevalent in periodontitis patients with
CVD, while type I fimA was found mainly in period-
ontally healthy subjects (8789). In addition, type IV P.
gingivalis exhibited higher hemagglutination activity,
whereas type II P. gingivalis was lower in trypsin-like,
arginine-specific activity (BAPNA) (90). In particular,
type II fimA P. gingivalis was reported to cause impaired
host cellular function including adhesion, migration, and
proliferation as this bacterial strain is able to degrade
focal adhesion kinase, paxillin, and integrin-related
signaling molecules at significantly greater levels than
other strains (78). This strain of fimA P. gingivalis was
also detected more frequently in deeper periodontal
pockets (91) and was the most efficient invader of human
epithelial cells compared with other P. gingivalis strains
(78). Using a mouse abscess model, Nakano et al. (92)
showed that among the six strains, fimA type II caused
the most significant induction of acute general inflam-
mation. Deletion of type II fimbriae led to a depletion in
the infection capabilities of the bacterium.
Leukotoxins
Leukotoxins are a group of exotoxins that have primary
toxic effects against leukocytes, particularly polymorpho-
nuclearcells (PMNs). Leukotoxin from A. actinomycetem-
comitans forms pores in the lipid bilayer and is capable of
killing human leukocytes via a specific receptor on the
cell membrane (reviewed in Narayanan et al. (93)). In
human PMNs and macrophages, leukotoxins trigger the
translocation of cytoplasmic granules to the periphery,
releasing the lysosomal contents, and increasing the
oxidative activity leading to inflammation-mediated
injury to host tissues (94). Leukotoxin also promotes
programmed cell death (apoptosis) by activating endogen-
ous nuclease that leads to an enhanced breakdown of
chromosomal DNA; killing PMNs, macrophages, natural
killer (NK) cells, and T lymphocytes (95). Importantly,
leukotoxin also helps A. actinomycetemcomitans to evade
the host immune system, allowing the bacterium to
establisha local infection. Leukotoxin also acts as abridge
tobindthebacteriumtoleukocytes,enablingthebacterium
to spread throughout host tissues unnoticed (reviewed in
Narayanan et al. (93)).
Capsule
Capsules protect bacteria from phagocytosis, aid in cell
attachment, and subsequent biofilm formation. Capsular
antigens are also targets of the immune system and are
involved in cell recognition (96). P. gingivalis strains with
a capsule are reported to be more virulent and invasive
compared with strains without a capsule (78).
Current evidence for the role of oral bacteria in
cardiovascular disease (CVD)
While many studies have shown an association between
oral infection and CVD, the relationship remains to be
established as a causal one. Intervention and pathogenic
mechanisticstudiesarerequiredtostrengthentheevidence
for the association between the two diseases. A number of
mechanisms have been proposed and incorporate both
direct and indirect effects of bacteria on the vasculature
(97).
A number of reviews have been published outlining the
development of atherosclerosis (1, 98, 99). The following
discussionwillprovideabriefoverviewofthedevelopment
of atherosclerosis and how oral bacteria may facilitate
and enhance this process.
Atherosclerosis is an immune/inflammatory disease
and presents as focal thickening of the intima (1). The
initiating factor in atherogenesis is endothelial dysfunc-
tion. Endothelial dysfunction occurs initially at sites of
arterial bifurcations, but risk factors such as hypercho-
lesterolemia and hypertension can also lead to patches of
endothelial dysfunction. Low density lipoprotein (LDL)
accumulates in the intima and in these areas becomes
oxidized (oxLDL). Activated endothelial cells express
cellular adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), and selectins that mediate rolling and adhe-
sion of circulating leukocytes, such as monocytes and
lymphocytes to the endothelial cells. Once adhered to the
cell surface, leukocytes migrate into the intima in
response to chemoattractant factors such as monocyte
chemoattractant protein-1 (MCP-1). Monocytes subse-
quently differentiate into macrophages, in response to
macrophage colony stimulating factor (M-CSF), engulf
oxLDL via scavenger receptors, and become foam cells
forming the first stage of the atherosclerotic lesion known
as the fatty streak (reviewed in Libby (98)).
T-cells (predominately CD4 cells) present within the
intima recognize antigens presented by the major histo-
compatability complex (MHC) molecules expressed on
the surface of antigen presenting cells and mount cell-
mediated immune responses. T helper 1 (Th1; cellular)
immunity is currently believed to be central in atherogen-
esis and involves proinflammatory mediators such as
interferon-gamma (INF-g), TNF-a, IL-1, and IL-12. The
role of T helper 2 (Th2; humoral) mediated immunity in
disease progression is still unclear (reviewed in Hansson
et al. (99) and Jawien (100)).
Pro-inflammatory cytokines produced by activated
macrophages or T-cells contribute to the local inflamma-
tion of the lesion and stimulate the migration and
proliferation of smooth muscle cells (SMCs). The
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nents that lead to the formation of a fibrous cap over the
lesion. As macrophages accumulate more lipid, apoptosis
occurs leading to a necrotic core of extracellular lipid
deposits that are covered by a fibrous cap (reviewed in
Libby (98)). A complication of the lesion is rupture
leading to thrombus formation and obstruction of the
vessel that can result in clinical signs of atherosclerosis
such as myocardial infarction and stroke (1). Vulnerable
lesions are generally characterized by a thin fibrous cap,
large necrotic lipid core, and numerous inflammatory
cells. Stable lesions, on the other hand, have a thick
fibrous cap, small necrotic lipid core, and numerous
SMCs (reviewed in Libby (98)). Inflammation, therefore,
is evident through all stages of lesion development and
not only plays a role in lesion development but also in
lesion instability and rupture.
The anatomical proximity of the oral biofilm to the
periodontal vasculature facilitates the systemic spread of
oralbacteriatodistantsitesfromtheoralcavitysuchasthe
heart (101). The sulcular epithelium is relatively thin and
easily disturbed (reviewed in Parahitiyawa et al. (102)).
Mastication, oral hygiene procedures (tooth brushing and
dental flossing) (103105), and periodontal procedures
(periodontal probing, tooth extractions, removal of sub-
gingivalplaqueandcalculus,aswellassurgery)candisturb
the sulcular epithelium leading to a bacteremic state (103,
104). In both gingivitis and periodontitis the periodontal
vasculature dilates, increasing in surface area, further
facilitating bacteremia (reviewed in Parahitiyawa et al.
(102)). Individuals with poor oral hygiene are at a higher
risk of developing bacteremia during periodontal proce-
dures due to a higher bacterial burden (104).
Direct arterial infection
It is hypothesized that transient bacteremia during period-
ontal infection may lead to direct bacterial invasion of
endothelial cells. Invasion of non-phagocytic cells is a
common strategy of pathogens to evade host defenses.
Indeed, bacteria, including those of oral origin, have
been identified by PCR in atherosclerotic plaques
(106110). Multiple oral bacteria (Streptococcus mutans,
Streptococcus sanguinis, A. actinomycetemcomitans, P.
gingivalis, and T. denticola) have been detected in both
aortic aneurysm specimens and in heart valve specimens
(111). Oral bacteria have also been frequently detected
at sites along the arterial tree where atherosclerotic
lesions commonly occur. For example, P. gingivalis, A.
actinomycetemcomitans, Prevotella intermedia, and T.
forsythia were commonly found in coronary arteries but
not in internal mammary arteries (96). Supporting this
finding, Ford et al. (109) identified P. gingivalis in 100% of
the carotid endarterectomy specimens examined and
F. nucleatum and T. forsythia in 84 and 48% of specimens,
respectively. Furthermore, two or more species of period-
ontal bacteria were detected in 64% of atherosclerotic
plaquesfromCHDpatientswithperiodontaldisease(112).
It is unclear, however, if the presence of oral bacteria in
atherosclerotic lesions contributes to the progression of
atherosclerosisorconstitutesaninnocentbystandereffect.
In support of direct effects of oral bacteria on
endothelial cells, invasive strains of P. gingivalis have
been shown to induce their uptake by macrophages and
enhance foam cell formation, in the presence of LDL, in
vitro (113). Furthermore, certain strains of P. gingivalis, P.
intermedia (114, 115), and S. mutans (116) have been
shown to invade and persist in vitro within aortic
endothelial cells. Following on from this, P. gingivalis
has been shown to replicate intracellularly within autop-
hagosomes (117). The ability of P. gingivalis, as well as
other bacteria, to persist intracellularly may allow the
establishment of secondary chronic infections that may
further contribute to the pathology of atherosclerosis.
Invasion of endothelial cells by bacteria can lead to
endothelial dysfunction, a key event in the development
of atherosclerosis. Endothelial dysfunction is associated
with increased procoagulant properties, mononuclear cell
adhesion, increased expression of cell adhesion mole-
cules, and proinflammatory cytokines and chemokines
(such as IL-6, IL-8, and MCP-1) all of which have been
shown to be induced by P. gingivalis (118, 119). These
proinflammatory and proatherogenic effects of P. gin-
givalis have been linked to the invasive capacity of the
bacterium as DPG3, a mutant form of P. gingivalis
lacking major fimbriae, was unable to induce these effects
in endothelial cells (118, 119). Bacterial invasion of host
cells can also result in apoptosis as high concentrations of
P. gingivalis, but not DPG3, were able to induce apoptotic
cell death of endothelial cells (120). Therefore, an
invasion of endothelial cells by oral bacteria may lead
to changes in the proinflammatory and proatherogenic
properties of endothelial cells as well as programmed cell




platelets. While the primary role of platelets is hemostasis,
they also play a role in the immune response to infection
(121). Oral bacteria may affect platelets directly or
indirectly. Firstly, the immune response to oral bacteria
may activate platelets; secondly, oral bacteria may secrete
products that activate platelets; and thirdly, bacteria may
bind to platelets resulting in activation (reviewed in
Kerrigan et al. (122)). Activation of platelets by bacteria
can lead to localized thrombus formation, platelet
consumption, as well as increased secretion of pro-
inflammatory cytokines and mediators from platelets,
which further contribute to the pathology of athero-
sclerosis (reviewed in Fitzgerald et al. (123)).
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viridans group, S. sanguinis, S. gordonii, S. mutans, and
S. mitis, have been found to induce platelet adhesion and
aggregation in vitro (reviewed in Kerrigan and Cox (124)).
The process is multifactorial and involves many cell
surface proteins including: the platelet aggregation asso-
ciated protein (PAAP) of S. sanguinis (125), serine rich
glycoproteins designated SrpA and GspB/Hsa in
S. sanguinis (126) and S. gordonii (127), respectively,
adhesions such as SspA and SspB in S. gordonii (122), as
well as glucosyltansferases (128).
Platelet aggregation is not limited to Streptococci
species as certain strains of P. gingivalis also induce
platelet aggregation in vitro. The platelet aggregating
ability of P. gingivalis was first attributed to fimbriae as
fimbriaed strains of P. gingivalis were potent activators of
murine platelets and the DPG3 mutant was ineffective at
inducing aggregation (129). Purified fimbriae alone,
however, was unable to induce platelet aggregation
suggesting that other factors, in addition to fimbriae,
must also be involved in the process (129). P. gingivalis
expresses a non-collagen like antigen that is cross-reactive
with PAAP of S. sanguinis (130); however, further
characterization of this antigen has not been carried
out to date.
Vesicles of P. gingivalis have been shown to induce
platelet aggregation (129). Vesicles are outgrowths of the
outer membrane and contain many virulence factors such
hemagglutinins, proteases, and LPS (131). It is proposed
that fimbriae are involved in the binding of the bacterium
to platelets and that the binding leads to the interaction
of surface expressed vesicle proteins with platelet recep-
tors leading to platelet aggregation (129). Further analy-
sis of the protein vesicles in platelet rich plasma showed
that P. gingivalis induced platelet aggregation was depen-
dent on cysteine proteases (Kgp and Rgp gingipains) and
adhesions such as Hgp44 (132). Recently, P. gingivalis
induced aggregation has also been shown to occur via a
TLR-2 dependent mechanism. To date, other periodontal
pathogens have not been observed to induce platelet
aggregation (129).
Systemic inflammation
Currently there is strong evidence to support the role
of systemic inflammation in the development and progres-
sion of atherosclerosis. Epidemiological studies have
shown that CV-risk is associated with increased levels of
cytokines (IL-1, IL-6, TNF-a, and MCP-1), and acute
phase proteins such as C-reactive protein (CRP) and
fibrinogen (133135). Furthermore, plasma levels of in-
flammatory markers such asCRP havebeenshown tobe a
stronger predictor of future CV events than LDL levels,
strengthening the importance of inflammation in the
progression of atherosclerosis (136). CRP has also been
shown to be directly involved in the development of
atherosclerosis. CRP stimulates the expression of cell
adhesion molecules on arterial endothelial cells, induces
the recruitment of monocytes into the arterial wall, and
stimulates LDL uptake by macrophages, thereby promot-
ing foam cell formation (reviewed in Libby (98)).
As outlined earlier, activated endothelial cells express
cellular adhesion molecules. These molecules can be shed
from the cell surface and soluble forms are markers of
endothelial activation. Indeed, elevated levels of soluble
(s) ICAM-1, sVCAM-1, and selectins have been asso-
ciated with CV-risk (137).
In relation to the systemic inflammation model it is
hypothesized that cytokines and inflammatory mediators
produced in periodontal disease act systemically to
promote systemic disease. In addition, the release of
bacteria and bacterial by-products such as LPS into the
circulation may also trigger a systemic inflammatory
response. Increased levels of circulating cytokines can
activate vascular endothelial cells, ultimately leading
to the development of atherosclerosis. In addition to
activating inflammatory cells, bacterial LPS may trigger
and enhance atherosclerosis by increasing oxidative stress
and modifying lipid metabolism (138).
A number of studies showed that patients with severe
periodontitis have increased levels of systemic inflamma-
tory markers (IL-6, CRP, haptoglobin, and leukocytosis)
(139144). In addition, periodontitis patients were also
found to exhibit dyslipidemia (145) and endothelial
dysfunction as assessed by flow-mediated dilatation of
the brachial artery (140).
Periodontalinterventionstudieshavebeenimplemented
to further investigate the contribution of periodontal
infection to systemic markers of inflammation and vascu-
larhealth.Intheshort-term(hoursto1week),periodontal
therapyappearstoelicitasystemicinflammatoryresponse
and mediate endothelial activation/dysfunction as a result
of transient bacteremia immediately following therapy
(146148).Inthelong-term,endothelialfunctionimproves
and is evident up to 6 months post-therapy (148, 149).
The long-term effects of periodontal therapy in relation
to systemic cytokine levels areinconsistent among studies,
especially with regard to the cytokines affected and
the time frame at which the effect was observed. Patients
receivingperiodontaltherapyinconjunctionwithsystemic
administration of antibiotics exhibited no significant
change in CRP, IL-6, or TNF-a following a 3 month
period (150). While Buhlin et al. (151) also failed to detect
changesinmarkersofinflammationatthesametimepoint,
levels of IL-8, INF-g, and haptoglobin were reduced and
lipid profiles improved 12 months after conventional
periodontal therapy. In contrast, periodontitis patients
receiving intensive periodontal therapy (standard period-
ontal therapy plus local administration of minocycline)
had significant reductions in IL-6, CRP, lipid markers,
and systolic blood pressure (SBP) 2 months post-therapy
Shaneen J. Leishman et al.
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alone. In addition, patients receiving intensiveperiodontal
therapy also displayed reductions in Framingham CV-risk
scores 2 and 6 months following therapy (152). In patients
with hypertension followed for 3 months, non-surgical
periodontal therapy resulted in reduced levels of CRP,
IL-6, and fibrinogen (153). Furthermore, while levels of
CRP, IL-6, and fibrinogen were reduced in patients with
and without CHD, changes in fibrinogen andwhite blood
cell count were higher in patients with CHD (154).
Tonetti et al. (148) demonstrated an improvement in
endothelial dysfunction and reduced levels of sE-selectin
and neutrophil counts 6 months post-therapy; however,
the study failed to detect differences in CRP, IL-6, and
plasminogen activator inhibitor-1 (PAI-1) between treat-
ment and control groups at the same time point. Period-
ontal therapy, including surgery, reduced levels of
vascular health (PAI-1, sE-selectin, sVCAM-1, MMP-9,
and myeloidperoxidase) in patients with periodontitis;
however, only reduced levels of sE-selectin were main-
tained 1 month after the completion of the periodontal
therapy regime (155). A summary inflammation score
used to assess the systemic inflammatory burden of each
patient indicated that there was a high degree of patient
variability in the systemic inflammatory response to
therapy. Thirty-three percent of patients experienced a
reduction in the inflammatory score, 25% experienced an
increase in the inflammatory score, while the remainder
of the patients experienced no change in the inflamma-
tory score following therapy (155). The apparent patient
variability in systemic inflammation may be due to host
genetic factors. Systemic inflammatory responses are
higher in periodontitis patients carrying alleles for
functional polymorphisms in IL-1a, IL-6, and TNF-a
genes (156) and these individuals may be more likely to
experience anti-inflammatory effects after periodontal
therapy.
Another marker of chronic inflammation is anemia.
Anemia of chronic diseases (ACD), as it is otherwise
known, is a cytokine-mediated anemia that is character-
ized by impaired mobilization of iron from reticuloen-
dothelial stores, reduced red blood cell survival, and
impaired erythropoiesis. Cytokines that have been impli-
cated in ACD include IL-1, IL-6, TNF-a, and INF-g
(reviewed in Means (157)). Periodontal infections have
been associated with anemia of chronic inflammation.
Periodontitis patients have been shown to exhibit an
anemic state as indicated by reduced hematocrit levels,
decreased erythrocyte numbers, and reduced hemoglobin
levels (158, 159). Intervention studies have further sup-
ported this association demonstrating that non-surgical
periodontal therapy can result in significant increases in
hemoglobinandhematocritlevelswithintreatmentgroups
(159) as well as compared with control patients who
received no periodontal therapy (160).
While there are inconsistencies among studies, the
general trend is that periodontal therapy can improve
systemic markers of inflammation and vascular health;
however, the long-term effects of this with regards to CV
events remain unknown. It is difficult to interpret the
results of the intervention studies due to differences in
periodontal therapy (including duration), time frame at
which samples were assessed, and the exclusion of
control, non-intervention, groups in some studies. A
recent meta-analysis of six studies investigating the effects
of periodontal therapy on CRP has provided further
insight into the strength of the relationship, and con-
cluded a modest association between periodontal therapy
and reduced levels of CRP (161).
The reduction in inflammatory markers after period-
ontal therapy provides evidence that the elevated levels of
systemic inflammation were due to periodontal disease
rather than other inflammatory conditions and supports
the hypothesis that periodontal inflammation may add to
the systemic inflammatory burden of affected individuals.
Cross-reactivity
There is increasing evidence that immune responses may
also be involved in the progression of atherosclerosis (97).
One mechanism in which infection may initiate and
facilitate the progression of atherosclerotic lesions can
be explained in terms of the immune response to bacterial
HSPs, termed GroEL (162).
HSPs are expressed by prokaryotic and eukaryotic cells
in response to various forms of stress (temperature,
mechanical stress, infection, and oxygen radicals) (163).
They are highly conserved throughout nature and many
pathogens express HSPs that are homologous to human
HSPs (164). During infection, bacterial HSPs are highly
immunogenic (165). Factors such as mechanical stress,
bacterial LPS, and cytokines may induce the expression
of host protective HSP60 (hHSP60) on endothelial cells.
Due to the homologous nature of HSPs across species,
the immune system may not be able to differentiate
between host and bacterial HSPs. As a result of this
molecular mimicry, there may be cross-reactivity of the
immune response to bacterial HSPs with HSPs expressed
by stressed endothelial cells leading to endothelial
dysfunction and subsequent development of athero-
sclerosis (162). The presence of CV-risk factors such as
hypertension and hypercholesterolemia would enhance
the expression of hHSP60 and adhesion molecules by
endothelial cells and result in progression from early
fatty streak lesions to more severe and irreversible
atherosclerotic alterations. Supporting this, Perschinka
et al. (166) identified that hHSP60 was expressed to
varying degrees in healthy arteries and atherosclerotic
lesions.
Elevated levels of antibodies to hHSP60 have been
associated with the presence and severity of coronary
CVD and roles of oral bacteria
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Metzler et al. (168) demonstrated a correlation between
high anti-HSP60/65 antibody levels and high morbidity
andmortalityduetoatherosclerosis.Theseantibodieswere
cross-reactive with other bacterial HSPs and were able to
lyse stressed  but not unstressed  endothelial cells (169).
Elevated anti-hHSP60 levels have also been found in
patients with carotid stiffness (170), borderline hyperten-
sion, and have been associated with early atherosclerosis
(171).
The mechanism by which antibodies to self-antigens,
such as hHSP60, are generated is unclear. It is currently
proposed that anti-hHSP60 antibodies could represent a
cross-reactive host immune response to bacterial HSPs in
susceptible individuals or result from a primary immune
response to altered self-HSP60 expression (172).
The GroEL proteins are major antigens in several
pathogenic bacterial (173). GroEL proteins and homo-
logues have been identified in several oral bacteria includ-
ing P. gingivalis, A. actinomycetemcomitans, F. nucleatum,
P. intermedia, T. denticola, and S. mutans (reviewed in
Goulhen et al. (174)). GroEL from P. gingivalis, F.
nucleatum, and A. actinomycetemcomitans was recognized
by serum antibodies in patients with periodontal disease
(175). Patients with periodontal disease have been shown
to have a higher antibody response to hHSP60 and
P. gingivalis GroEL compared with periodontally healthy
controls. In addition, these antibodies were cross-reactive
with P. gingivalis GroEL and hHSP60, respectively (176).
Due to the homologous nature of bacterial GroEL
with hHSP60, periodontal infections have been asso-
ciated with atherosclerosis possibly due to cross-reactivity
of the immune response to bacterial GroEL with
hHSP60. Previous studies have demonstrated the pre-
sence and cross-reactivity of hHSP60, P. gingivalis
GroEL, and P. gingivalis specific T-cells in the gingival
tissues of chronic periodontitis patients (177), in the
peripheral blood of atherosclerotic patients, and in
human atherosclerotic lesions (178). Furthermore, anti-
bodies to P. gingivalis from atherosclerotic patients with
periodontitis cross-reacted with hHSP60 (109). In an
intervention study, Yamazaki et al. (179) found that
periodontal therapy significantly reduced the levels of
anti-P. gingivalis GroEL antibodies in patients with
moderate to advanced periodontal disease, while the
mean levels of antibodies to hHSP60 remained un-
changed. Similarly, Buhlin et al. (151) detected no change
in anti-hHSP60 antibody levels following periodontal
therapy.
Murine models of atherosclerosis have also provided
evidence for the role of HSP immunity in atherosclerosis.
Immunization of C57BL/6 mice fed a cholesterol rich diet
with HSP resulted in enhanced atherosclerosis (180).
Furthermore, an injection of human anti-hHSP60 anti-
bodies in apoE (/) mice enhanced atherosclerosis
(181). This is supported by an intervention study that
demonstrated protection from atherosclerosis following
oral tolerance to HSP60 (182). In addition, Ford et al. (21)
showed a significant correlation between anti-GroEL
antibody levels and atherosclerotic lesion size in apoE
(/) mice inoculated with P. gingivalis, indicating that
molecular mimicry may be a mechanism involved in
infection-induced atherosclerosis.
Conclusion
There is clear evidence of an epidemiological association
between oral infections and CVD and in vitro and in vivo




Recent studies provide strong support for the roles of
systemic inflammation and immune cross-reactivity in
atherogenesis. Furthermore, intervention studies have
demonstrated that periodontal therapy can reduce
systemic markers of inflammation and vascular health
as well as antibody responses to heat shock proteins.
Future studies are now required to determine the long-
term effects of periodontal therapy on CVD outcomes.
Nevertheless, a recent consensus report on periodontitis
and atherosclerotic CVD, published in the American
Journal of Cardiology and the Journal of Periodontology
(183), has recommended that patients with moderate to
severe periodontitis should be informed of a possible
increased risk of CVD and those with more than one
CV-risk factor should undergo a medical evaluation of
CV-risk.
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